I am not sure about the source of your information but as per the protocol of the study the likely timeframe for completion of the study is June 2022!
Statistical analysis and understanding of results will follow that. Then presentation of data in a suitable setting.
One just can't detail anything about the trial as it breaks the intellectual rigour of the study.
In the scenario of a positive result, the company will apply to drug authorities in various jurisdictions around the globe and they will respond accordingly.
IMHO, the scenario of CSL112 (if effective) being approved for usage is three to four years away.
Ann: CSL Half Year Results Investor Presentation, page-9
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$288.93 |
Change
0.320(0.11%) |
Mkt cap ! $139.9B | |||
| Open | High | Low | Value | Volume |
| $287.64 | $289.70 | $287.16 | $174.5M | 601.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 149 | $288.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $288.96 | 1858 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |